Success Stories: EB1A Approval for a Post-Doctoral Researcher in the Field of Cell and Molecular Biology in 4.5 months
On October 3rd, 2013, we received another EB1A Approval for a Post-Doctoral Researcher in the Field of Cell and Molecular Biology (Approval Notice)
General Field: Cell and Molecular Biology; Biochemistry; Pharmacology; Pharmacogenomics
Position at the Time of Case Filing: Research Scientist
Country of Origin: India
Service Center: Nebraska Service Center
State of Residence at the Time of Filing: California
Approval Notice Date: October 3, 2013
Processing Time: 4 ½ months
Case Summary:
Another exceptional client with whom North America Immigration Law Group – WeGreened.com had the pleasure of working was a post-doctoral research scientist from India whose research has influenced the fields of molecular and cell biology, biochemistry, and pharmacogenomics. In his most recent endeavor, our client studied the pathophysiology of Leishmaniasis and its mechanism of hemoglobin metabolism. Incapable of synthesizing heme themselves, Leishmania parasites must imbibe hemoglobin from their hosts to survive. Infected female sandflies transmit these parasites to humans in regions including southern Europe, parts of Asia, Central and South America, and Africa. Annually, Leishmaniasis affects 12 million people in 88 nations and kills around 60,000, including U.S. troops and aid organization volunteers stationed in these countries. Through biochemical analysis, our client became the first scientist to identify the protein Rab7 as the vehicle responsible for the intracellular intake and transport of hemoglobin to lysosomes in Leishmania. In pinpointing the protein responsible for the parasite’s acquisition of nutrients, our client was furthermore able to design a less toxic therapeutic treatment for Leishmania specifically targeting the Rab7 protein. We at North America Immigration Law Group – WeGreened.com demonstrated that our client qualified for classification as an Alien of Extraordinary Ability, that through his research he had risen to the top of his field, and that his continued research would substantially and prospectively benefit the United States. We offered that this client’s 11 publications had appeared in peer-reviewed journals with large impact factors and had been cited 133 times at the time of filing. We submitted evidence of our client’s editing services for 17 different journals, including two editorial board positions. Additionally, we highlighted other major research accomplishments concerning our client’s broad expertise in confocal microscopy, sickle cell disease research, and pathogenesis of dry eye disease. Of these accomplishments, an independent recommender commented: “[client]’s astounding research results are highly regarded and demanded in the fields of Microbiology and Cell Biology…I eagerly await the influential results of [Client]'s continual research, which will give new optimism to those suffering from nay life-threatening conditions.” Through such expert testimonies and the extensive documentation we provided, we successfully demonstrated our client’s research to be of extraordinary quality. His EB1A application was approved 4 ½ months after its filing.